Cryosite (ASX:CTE) grows EBITDA 27% and now the capacity question takes over

Ferndell Street is filling up, Adderley Street is coming online, and FY27 is a pure conversion story.

Cryosite (ASX:CTE) has closed out FY2026 with the kind of numbers that make small-cap earnings watchers pay attention. Revenue up 18% to A$16.7m, EBITDA up 27% to A$4.3m, and margins expanding by 1.8 percentage points to 25.7%.

The story of the year is that earnings grew faster than revenue, which is exactly what you want to see from a specialist services business with a fixed cost base. The Ferndell Street headquarters filled up, operating leverage kicked in, and the fourth quarter carried the momentum through to a June exit run rate of A$1.5m in monthly revenue.

For a company that stores and moves clinical trial samples and biological products across ambient, cold, frozen, ultra-frozen and liquid nitrogen conditions, this kind of quiet compounding is the whole game. There is no blockbuster contract to announce and no transformative acquisition. Just capacity, utilisation, and margin.

The interesting part is what comes next. Ferndell Street’s cool room expansion is done, the Adderley Street facility build is progressing, and management now has meaningfully more square metres to fill in FY27.

The margin story is doing the heavy lifting

The revenue line grew 18%, which is respectable. The EBITDA line grew 27%, which is the number that actually matters here. Operating leverage in a facility-based services business only appears once utilisation crosses a threshold, and Cryosite is clearly through that point at Ferndell Street.

EBITDA margin of 25.7% for a sub-A$20m revenue business in specialist logistics is genuinely strong. NPAT margin of 13.5% translates to A$2.3m of net profit, up 20% on the prior year. On an unaudited basis these are clean numbers, and there is nothing in the release that suggests one-offs are flattering the result.

We think the market often underestimates how much operating leverage a niche depot business can generate once the base facility is paid for. The question is whether Adderley Street can repeat the trick without eating into group margins during the ramp.

Adderley Street is the FY27 swing factor

The Adderley Street facility adds roughly 2,100 square metres of building area with 9.1 metre clearance, sitting 15 minutes from the Ferndell Street headquarters. It expands the clinical trial and biological services footprint and opens up medical devices, reverse logistics and pallet storage as adjacent revenue lines.

The commercial logic is straightforward. Ferndell Street was becoming the constraint, and adding a second site lets Cryosite say yes to enquiries it previously had to turn away or defer. The strategic logic is that medical device logistics is a genuinely different customer base to biological samples.

Our concern is the standard one for any capacity expansion. Empty square metres are a cost centre until they are full, and the ramp period will almost certainly compress group margins before it lifts them. Management has flagged a strong client pipeline, but a pipeline is not a signed contract.

Why the pipeline claim needs quarterly proof

Management describes the client pipeline as strong and points to converting additional capacity into client activity as the FY27 focus. That framing is exactly right, but it also means FY27 is a show-me year. The Ferndell Street utilisation story is now largely priced in.

The skeptical read is that clinical trial logistics is a relationship business with long sales cycles, and the incremental revenue from Adderley Street may not fully arrive until FY28. Investors should watch the quarterly cash flow reports for evidence that new client contracts are landing rather than waiting for the annual result.

The optimistic read is that having two GMP-capable sites in Sydney’s west, with materially different service offerings, makes Cryosite a harder pitch for pharma sponsors and CROs to walk past.

The Investors Takeaway for Cryosite

FY26 was the year Cryosite proved the operating leverage thesis works at its headquarters. FY27 is the year investors find out whether that same playbook runs at Adderley Street, with a broader service mix and a partially different customer base.

We think the setup is genuinely constructive. A profitable, cash-generative specialist with 25.7% EBITDA margins, a completed capacity expansion and a second site coming online is not a common combination at this end of the ASX. The audit still needs to close out these numbers, and pipeline conversion still needs to show up in the quarterlies, but the base case looks solid.

Investors can find more coverage of specialist ASX small-cap services businesses at stocksdownunder.